---
title: "Qulipta (atogepant) in preventive treatment of migraine: Drug interactions questions"
description: "Drug interactions questions on Qulipta (atogepant) in preventive treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drugs interact with Qulipta? Can Qulipta be taken with strong CYP3A4 inhibitors such as itraconazole? Can Qulipta be taken with CYP3A4 inducers such as rifampin? What is the Qulipta dose with OATP inhibitors? 5 further questions follow. 9 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/drug-interactions"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Qulipta (atogepant) in preventive treatment of migraine: Drug interactions questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Qulipta](https://www.rxabbvie.com/pdf/qulipta_pi.pdf)

## Drug interactions

<a id="qulipta-drug-interactions"></a>

### What drugs interact with Qulipta?

> “Recommended dosage modifications:  
> • Strong CYP3A4 Inhibitors (2.2, 7.1):  
> o Episodic or chronic migraine: 10 mg once daily 
> • Strong CYP3A4 Inducers (2.2, 7.2):  
> o Episodic migraine: 60 mg once daily (monitor for reduced efficacy). 
> o Chronic migraine: Not recommended. 
> • 
> Moderate CYP3A4 Inducers (2.2, 7.2): 
> o Episodic migraine: 60 mg once daily. 
> o Chronic migraine: Not recommended. 
> • Weak CYP3A4 Inducers (2.2, 7.2): 
> o Episodic migraine: 30 mg or 60 mg once daily. 
> o Chronic migraine: 60 mg once daily. 
> • OATP Inhibitors (2.2, 7.3):  
> o Episodic migraine: 10 mg or 30 mg once daily.  
> o Chronic migraine: 30 mg once daily.”

Source: [QULIPTA: Prescribing information, page 1, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=1)

> “Atogepant is not anticipated to be a clinically significant perpetrator of 
> drug-drug interactions through CYP450s, MAO-A, or UGT1A1 inhibition.”

Source: [QULIPTA: Prescribing information, page 10, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=10)

> “For chronic migraine, concomitant use of strong or moderate CYP3A4 inducers with QULIPTA is not recommended.<sup>1</sup>”

Source: [QULIPTA: Frequently Asked Questions for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/frequently-asked-questions#:~:text=For%20chronic%20migraine%2C%20concomitant%20use,inducers%20with%20QULIPTA%20is%20not)

On the page, select: What medications should not be taken with QULIPTA?

Note: The first passage is the Drug Interactions summary in the Highlights of the Prescribing Information; the numbers in parentheses refer to label sections.

<a id="qulipta-cyp3a4-inhibitors"></a>

### Can Qulipta be taken with strong CYP3A4 inhibitors such as itraconazole?

> “Coadministration of QULIPTA with itraconazole, a strong CYP3A4 inhibitor, resulted in a 
> significant increase in exposure of atogepant in healthy subjects [see Clinical Pharmacology 
> (12.3)]. The recommended dosage of QULIPTA with concomitant use of strong CYP3A4 
> inhibitors is 10 mg once daily [see Dosage and Administration (2.2)]. No dosage adjustment of 
> QULIPTA is needed with concomitant use of moderate or weak CYP3A4 inhibitors.”

Source: [QULIPTA: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=5)

> “Co-administration of QULIPTA with itraconazole, a strong CYP3A4 inhibitor, resulted in a 
> clinically significant increase (Cmax by 2.15-fold and AUC by 5.5-fold) in the exposure of 
> atogepant in healthy subjects [see Drug Interactions (7.1)].  
> Physiologically based pharmacokinetic (PBPK) modeling suggested co-administration of 
> QULIPTA with moderate or weak CYP3A4 inhibitors increase atogepant AUC by 1.7- and 
> 1.1-fold, respectively. The changes in atogepant exposure when coadministered with weak or 
> moderate CYP3A4 inhibitors are not expected to be clinically significant.”

Source: [QULIPTA: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=11)

<a id="qulipta-cyp3a4-inducers"></a>

### Can Qulipta be taken with CYP3A4 inducers such as rifampin?

> “Coadministration of QULIPTA with steady-state rifampin, a strong CYP3A4 inducer and 
> OATP1B1 and OATP1B3 inhibitor, resulted in a significant decrease in exposure of atogepant in 
> healthy subjects [see Clinical Pharmacology (12.3)]. Concomitant administration of QULIPTA 
> with moderate inducers of CYP3A4 can also result in decreased exposure of atogepant. 
> Coadministration of QULIPTA with steady-state topiramate, a weak CYP3A4 inducer, resulted 
> in decreased exposure of atogepant in healthy subjects [see Clinical Pharmacology (12.3)]. 
> For episodic migraine, the recommended dosage of QULIPTA with concomitant use of strong or 
> moderate CYP3A4 inducers is 60 mg once daily. During concomitant use of QULIPTA with 
> strong CYP3A4 inducers, monitor monthly for signs of reduced efficacy, and consider 
> alternative therapies if a reduction in efficacy is observed. The recommended dosage of 
> QULIPTA with concomitant use of weak CYP3A4 inducers is 30 mg or 60 mg once daily [see 
> Dosage and Administration (2.2)].”

Source: [QULIPTA: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=5)

> “For chronic migraine, concomitant use of strong or moderate CYP3A4 inducers with QULIPTA 
> is not recommended. The recommended dosage of QULIPTA with concomitant use of weak 
> CYP3A4 inducers is 60 mg once daily. Monitor monthly for signs of reduced efficacy, and 
> consider alternative therapies if a reduction in efficacy is observed [see Dosage and 
> Administration (2.2)].”

Source: [QULIPTA: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=6)

Note: Episodic and chronic migraine have different recommendations: the first passage ends with the episodic migraine dosages, and the second gives the chronic migraine recommendations.

<a id="qulipta-oatp-inhibitors"></a>

### What is the Qulipta dose with OATP inhibitors?

> “Coadministration of QULIPTA with single dose rifampin, an OATP inhibitor, resulted in a 
> significant increase in exposure of atogepant in healthy subjects [see Clinical Pharmacology 
> (12.3)]. For episodic migraine, the recommended dosage of QULIPTA with concomitant use of 
> OATP inhibitors is 10 mg or 30 mg once daily. For chronic migraine, the recommended dosage 
> of QULIPTA with concomitant use of OATP inhibitors is 30 mg once daily [see Dosage and 
> Administration (2.2)].”

Source: [QULIPTA: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=6)

<a id="qulipta-topiramate-interaction"></a>

### Can Qulipta and topiramate be taken together?

> “Coadministration of QULIPTA with steady-state topiramate, a weak CYP3A4 inducer, resulted in decreased exposure of atogepant in healthy subjects.
>
>
> Co-administration of QULIPTA with topiramate did not result in clinically significant changes in the pharmacokinetics of topiramate.”

Source: [QULIPTA: Frequently Asked Questions for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/frequently-asked-questions#:~:text=Coadministration%20of%20QULIPTA%20with%20steady%2Dstate,in%20the%20pharmacokinetics%20of%20topiramate.)

On the page, select: Can QULIPTA and topiramate be taken together?

> “Co-administration of 
> QULIPTA with topiramate, a weak inducer of CYP3A4, decreased atogepant mean steady-state 
> AUC 0-τ by 25% and mean steady-state Cmax by 24% in healthy subjects [see Drug Interactions 
> (7.2)].”

Source: [QULIPTA: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=11)

> “The recommended dosage of 
> QULIPTA with concomitant use of weak CYP3A4 inducers is 30 mg or 60 mg once daily”

Source: [QULIPTA: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=5)

> “The recommended dosage of QULIPTA with concomitant use of weak 
> CYP3A4 inducers is 60 mg once daily. Monitor monthly for signs of reduced efficacy, and 
> consider alternative therapies if a reduction in efficacy is observed [see Dosage and 
> Administration (2.2)].”

Source: [QULIPTA: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=6)

> “Co-administration of QULIPTA with topiramate did not result in clinically significant 
> changes in the pharmacokinetics of topiramate.”

Source: [QULIPTA: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=11)

Note: The label names topiramate as a weak CYP3A4 inducer. The third passage is the recommendation for episodic migraine and the fourth for chronic migraine.

<a id="qulipta-ubrelvy-interaction"></a>

### Can Qulipta and Ubrelvy (ubrogepant) be taken together?

> “Coadministration of QULIPTA with UBRELVY did not result in significant pharmacokinetic interactions.<sup>1</sup> The Phase 3 studies for UBRELVY and QULIPTA that supported product approval had no patients on concomitant medication that acted on the CGRP pathway.<sup>1,7</sup> Clinical conclusions of safety and efficacy should not be drawn from PK studies.”

Source: [QULIPTA: Frequently Asked Questions for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/frequently-asked-questions#:~:text=Coadministration%20of%20QULIPTA%20with%20UBRELVY,be%20drawn%20from%20PK%20studies.)

On the page, select: Can you take QULIPTA and UBRELVY® (ubrogepant) together?

> “Co-administration of QULIPTA with oral contraceptive components ethinyl estradiol and 
> levonorgestrel, famotidine, esomeprazole, acetaminophen, naproxen, sumatriptan, or ubrogepant 
> did not result in significant pharmacokinetic interactions for either atogepant or co-administered 
> drugs.”

Source: [QULIPTA: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=11)

Note: The FAQ on the Qulipta HCP site names the product UBRELVY® (ubrogepant); the Prescribing Information sentence (section 12.3) names ubrogepant. The FAQ cites the QULIPTA Prescribing Information (its reference 1) and the UBRELVY package insert (its reference 7) for its second sentence.

<a id="qulipta-birth-control-interaction"></a>

### Does Qulipta interact with birth control pills?

> “Co-administration of QULIPTA with oral contraceptive components ethinyl estradiol and 
> levonorgestrel, famotidine, esomeprazole, acetaminophen, naproxen, sumatriptan, or ubrogepant 
> did not result in significant pharmacokinetic interactions for either atogepant or co-administered 
> drugs.”

Source: [QULIPTA: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=11)

Note: The label reports pharmacokinetic studies; the sentence covers all the drugs listed.

<a id="qulipta-acute-medication-interactions"></a>

### Does Qulipta interact with sumatriptan, naproxen, or acetaminophen?

> “Co-administration of QULIPTA with oral contraceptive components ethinyl estradiol and 
> levonorgestrel, famotidine, esomeprazole, acetaminophen, naproxen, sumatriptan, or ubrogepant 
> did not result in significant pharmacokinetic interactions for either atogepant or co-administered 
> drugs.”

Source: [QULIPTA: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=11)

Note: The label reports pharmacokinetic studies; the sentence covers all the drugs listed.

<a id="qulipta-grapefruit"></a>

### What does the Qulipta label say about grapefruit juice?

> “Inform patients that QULIPTA may interact with certain other drugs, and that dosage 
> modifications of QULIPTA may be recommended when used with some other drugs. Advise”

Source: [QULIPTA: Prescribing information, page 20, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=20)

> “patients to report to their healthcare provider the use of any other prescription medications,”

Source: [QULIPTA: Prescribing information, page 20, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=20)

> “over-the-counter medications, herbal products, or grapefruit juice [see Dosage and 
> Administration (2.2) and Drug Interactions (7.1, 7.2, 7.3)].”

Source: [QULIPTA: Prescribing information, page 21, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=21)

Note: The passages are from Patient Counseling Information (section 17); the sentence continues from page 20 to page 21 of the Prescribing Information.

## Related pages
- [Medical information: Qulipta (atogepant): Preventive treatment of migraine](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/safety)
- [Specific populations](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/access-and-coverage)
